"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
NOTCH1 mutations, found in 20% of CLL cases, are associated with poor outcomes in chemotherapy but not yet in treatment guidelines. A retrospective analysis showed improved PFS for NOTCH1-mutated CLL ...
Test plugins are used to support different test frameworks than JUnit4. They are officially supported by gradle-pitest-plugin staring with version 1.1.4 (although it was possible to use it since 1.1.0 ...
Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...
The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering ...
Traditional biochemical methods of studying human gene mutations are often laborious and costly. Now bioengineers at the University of California San Diego have developed a new simple approach to ...
This Reading Room is a collaboration between MedPage Today® and: Patients who had genetic testing for BRCA mutations prior to breast cancer diagnosis had smaller tumors, less nodal involvement, and ...
Cancer is often caused by genetic mutations, which can lead to abnormal cell growth in the body. One type is called the KRAS G12C mutation, which happens in the KRAS protein.[1] KRAS acts as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results